Allosteric Modulation of M₁ Muscarinic Acetylcholine Receptor Internalization and Subcellular Trafficking

Holly R. Yeatman, J. Robert Lane, Kwok Ho Christopher Choy, Nevin A. Lambert, Arthur Christopoulos, and Meritxell Canals

From the Department of Pharmacology and Toxicology, Georgia Regents University, Augusta, Georgia 30912 and the Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Victoria 3052, Australia

Received for publication, November 20, 2013, and in revised form, April 14, 2014 Published, JBC Papers in Press, April 21, 2014, DOI 10.1074/jbc.M113.536672

Allosteric modulators are an attractive approach to achieve receptor subtype-selective targeting of G protein-coupled receptors. Benzyl quinolone carboxylic acid (BQCA) is an unprecedented example of a highly selective positive allosteric modulator of the M₁ muscarinic acetylcholine receptor (mAChR). However, despite favorable pharmacological characteristics of BQCA, there is limited evidence of the impact of allosteric modulation on receptor regulatory mechanisms such as β-arrestin recruitment or receptor internalization and endocytic trafficking. In the present study we investigated the impact of BQCA on M₁ mAChR regulation. We show that BQCA potentiates agonist-induced β-arrestin recruitment to M₁ mAChRs using a bioluminescence resonance energy transfer approach to monitor intracellular trafficking of M₁ mAChRs, we show that once internalized, M₁ mAChRs traffic to early endosomes, recycling endosomes and late endosomes. We also show that BQCA potentiates agonist-induced subcellular trafficking. M₁ mAChR internalization is both β-arrestin and G protein-dependent, with the third intracellular loop playing an important role in the dynamics of β-arrestin recruitment. As the global effect of receptor activation ultimately depends on the levels of receptor expression at the cell surface, these results illustrate the need to extend the characterization of novel allosteric modulators of G protein-coupled receptors to encapsulate the consequences of chronic exposure to this family of ligands.

Muscarinic acetylcholine (ACh) receptors (mAChRs) are an important subfamily of class A G protein-coupled receptors (GPCRs). Of the five mAChR subtypes, the M₁ mAChR has attracted particular attention for the treatment of several CNS disorders (1, 2). The M₁ mAChR couples predominantly to Gα₁/11 G proteins, leading to phospholipase Cβ-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate and subsequent calcium mobilization from intracellular stores (3). In the brain the M₁ mAChR is concentrated in forebrain structures such as the frontal cortex and hippocampus, where it is implicated in memory processing and cognition (4), and as such, M₁ mAChRs have been suggested as a target for the development of cognitive enhancers for conditions such as Alzheimer disease (5). Unfortunately, achieving subtype selectivity at mAChRs is challenging given the highly conserved nature of the orthosteric site across the mAChR family. Despite considerable efforts, only moderately selective orthosteric ligands have been developed (1). Increased subtype selectivity has been achieved by recent progress in the development of allosteric ligands, which bind to a topographically distinct site from the orthosteric site. An exemplar molecule in this regard is the M₁ mAChR-selective allosteric modulator, benzyl quinolone carboxylic acid (BQCA), which exhibits in vivo efficacy as a potentiator of ACh and has the potential to ameliorate impairments in cognitive function (6, 7). In a recent mechanistic study, we found that interaction between BQCA and the M₁ mAChR is consistent with a two-state model of receptor activation (8) whereby BQCA exhibits positive cooperativity with orthosteric agonists but negative cooperativity with inverse agonists in a manner that correlates with orthosteric ligand efficacy and stimulus-response coupling of the receptor (8). Additionally, BQCA does not engender pathway-biased signaling by orthosteric agonists at the M₁ mAChR (8). These prop-

Background: The effects of allosteric modulators on G protein-coupled receptor trafficking are largely unknown.

Results: The allosteric ligand BQCA modulates M₁ mAChR arrestin recruitment and receptor trafficking.

Conclusion: M₁ mAChR trafficking is arrestin- and G protein-dependent and modulated by BQCA.

Significance: The impact of allosteric modulators on receptor trafficking needs to be assessed when considering this family of ligands as potential chronic therapies.
properties make BQCA a very useful chemical tool with which to probe basic allosteric mechanisms at the M₁ mAChR as a model for general understanding of allostery at GPCRs. However, although the acute signaling profiles of M₁ mAChR allosteric ligands have been extensively characterized (8–10), the understanding of their impact on longer term receptor regulatory processes is currently limited in scope, and some reports to date are contradictory (11). Yet, understanding such processes is vital as most drug therapies involve chronic administration.

Upon activation, GPCRs are rapidly phosphorylated within intracellular loop 3 (ICL3) or the C-terminal tail either by second messenger kinases (such as PKA or PKC) or by GPCR kinases (GRKs). Phosphorylation of the receptor increases its affinity for the scaffolding protein β-arrestin, binding of which prevents further G protein-mediated signaling (12). Once β-arrestins associate with a GPCR, they scaffold the receptor to components of the clathrin-dependent endocytic machinery and promote receptor internalization. The two isoforms of β-arrestin (β-arrestin-1 and 2) interact with multiple intracellular signaling partners such as MAPks, protein kinase B/Akt, and protein phosphatases such as protein phosphatase 2A (13) and accordingly can also scaffold the receptor to distinct G protein-independent signaling pathways. Dissociation of β-arrestin from the GPCR occurs either at the cell surface or within endosomes, and the dynamics of such uncoupling have a profound impact on the subsequent fate of the desensitized receptor (14).

Here we show that M₁ mAChR internalization is both β-arrestin and G protein-dependent and that the third intracellular loop plays an important role in the dynamics of β-arrestin recruitment. We also exploit the unique properties of BQCA as a tool with which to systematically investigate the impact of allosteric modulation on M₁ mAChR trafficking and regulatory mechanisms. We show that BQCA potentiates agonist-induced β-arrestin recruitment to M₁ mAChRs and receptor endocytosis. Once internalized, M₁ mAChRs traffic to early endosomes, recycling endosomes and late endosomes. BQCA does not alter these trafficking profiles. However, we show for the first time that BQCA potentiates the trafficking of receptors within the different endocytic compartments. These results provide a framework to extend the characterization of allosteric modulators from acute signaling events into receptor regulatory processes, a dimension that must be investigated when considering the chronic use of these ligands.

EXPERIMENTAL PROCEDURES

Materials—Dulbecco’s modified Eagle’s medium, Hanks’ balanced salt solution, FlpIn Chinese hamster ovary (CHO) cells, penicillin/streptomycin, ProLong Gold, and Fluoro-4-AM were purchased from Invitrogen. HygroGold was purchased from InvivoGen (San Diego, CA). Fetal bovine serum was purchased from In Vitro Technologies (Noble Park, VIC, Australia). Polyethyleneimine was from Polysciences (Warrington, PA). N-[³H]Methylscopolamine ([³H]NMS) and Optiphase scintillation mixture were from PerkinElmer Life Sciences. Coelenterazine h was purchased from Promega (Alexandria, NSW, Australia). Dynasore was purchased from Tocris Bioscience (Bristol, UK). Pitstop2 was purchased from Abcam (Cambridge, MA). UBO-QIC was purchased from the Institute of Pharmaceutical Biology, University of Bonn (Germany). All other reagents were purchased from Sigma. BQCA was synthesized in-house.

YFP-β-arrestin-1 and 2 constructs were gifts from Marc Caron (Duke University). Venus-Rab5a, Rab7a, and Rab11 constructs were generated as previously described (15). The M₁ R123L mAChR mutation was generated using the QuikChange site-directed mutagenesis kit (Agilent Technologies, La Jolla, CA) following the manufacturer’s instructions. p416GPD-M₁Δi3 was a gift from Jürgen Wess (NIDDK, National Institutes of Health). The M₁, M₁R123L, and M₁Δi3-Rluc8 constructs were generated by replacement of the stop codon with a NotI linker followed by fusion of the cDNA in-frame to Rluc8 in pcDNA3.1.

Cell Culture and Transfections—FlpIn CHO cells stably expressing the WT, Δi3, or R123L hM₁ mAChRs were generated and cultured as described previously (16). Transient transfections of adherent HEK293 cells were performed using linear polyethyleneimine (molecular mass, 25 kDa) in a 1:6 ratio (8).

Inositol 1-Phosphate Accumulation—Inositol 1-phosphate production in M₁ mAChR FlpIn CHOs was measured using the IP-One assay kit (Cisbio) as described previously (17). Data were normalized to the maximum response generated by carbachol (CCh) alone.

Calcium Mobilization—M₁ mAChR FlpIn CHO cells were cultured overnight in 96-well plates at 37 °C in 5% CO₂. Cells were washed twice in Ca²⁺ assay buffer (150 mM NaCl, 2.6 mM KCl, 1.2 mM MgCl₂, 10 mM glucose, 10 mM HEPES, 2.2 mM CaCl₂, 0.5% (w/v) BSA, and 4 mM probenecid) then incubated in assay buffer containing 1 μM Fluo-4-AM for 1 h at 37 °C in 5% CO₂. Ligands were added, and the fluorescence was quantified in a Flexstation (Molecular Devices, Sunnyvale, CA) using 485-nm excitation and 520-nm emission wavelengths. The peak height of calcium fluorescence was calculated in SoftMax Pro (Molecular Devices) and used in subsequent statistical analyses.

Radioligand Binding—Cells were plated at 20,000 per well in a 96-well Isoplate (PerkinElmer Life Sciences) and allowed to adhere for at least 16 h. Cells were washed 3 times with binding buffer (146 mM NaCl, 10 mM d-glucose, 5 mM KCl, 1 mM MgSO₄, 2 mM CaCl₂, 1.5 mM NaHCO₃, 10 mM HEPES, pH 7.45) and incubated overnight with 4 nM [³H]NMS (specific activity 85.5 mmol/Ci) at 4 °C; any nonspecific binding was determined by the co-addition of 10 μM atropine. For saturation binding assays, cells were incubated overnight at 4 °C with increasing concentrations of [³H]NMS. After washing in cold saline, bound [³H]NMS was solubilized in Optiphase scintillant, and radioactivity was measured in an MicroBeta counter (PerkinElmer Life Sciences).

ELISA—HEK293 cells were transfected with 5 μg of c-myc-hM₁ or empty vector. 24 h post-transfection, cells were plated in poly-d-lysine-coated 48-well culture plates, allowed to adhere, and then grown overnight in serum-free media containing antibiotics. Cells were pretreated with cycloheximide (10 μg/ml) in serum-free media for 30 min before the addition of ligands, which were prepared in cycloheximide-containing media. Inhibitors of internalization were applied during the
pretreatment period and throughout ligand application. To assess receptor recycling, cells were thoroughly washed after ligand incubation, and fresh serum-free medium containing cycloheximide was re-applied. Inhibitors of recycling, when used, were applied from pretreatment through to the end of the washout step. At the conclusion of the incubation period, cells were washed gently 3 times with TBS and fixed in 3.7% v/v paraformaldehyde. Surface or total myc-hM1 receptors were detected in intact or (Nonidet P-40 equivalent)-detergent permeabilized cells, respectively, using the 9E10 mouse anti-myc antibody (1:2000) followed by HRP-conjugated goat anti-mouse IgG (1:2000). After washing with TBS, the peroxidase substrate (SIGMAFAST™ OPD) was added at a final concentration of 0.4 mg/ml, and the reaction was terminated by the addition of 1 M HCl. The colored reaction product was detected at 490 nm in a multi-label plate reader (EnVision, PerkinElmer Life Sciences). The absorbance values for transfected cells were normalized to those of mock-transfected cells, and receptor density was reported relative to vehicle-treated wells.

**Bioluminescence Resonance Energy Transfer (BRET)—** HEK293 cells were transfected with 1 μg of Rlu8-tagged M₁ and 4 μg of YFP-β-arrestin or 0.5 μg of Rlu8-tagged M₁, and 2 μg of Venus-Rab5a, Rab7a, or Rab11. Twenty-four hours post-transfection, cells were plated in poly-D-lysine-coated 96-well CulturPlates (PerkinElmer Life Sciences) and grown overnight. Cells were allowed to equilibrate in Hanks’ balanced salt solution containing 0.05% w/v bovine serum albumin at 37 °C in the presence or absence of specific inhibitors. For kinetic experiments, coelenterazine h was added at a final concentration of 5 μM, and BRET readings were immediately captured using a LUMItstar Omega instrument (BMG LabTech, Offenburg, Germany) that allows for sequential integration of the signals detected at 475 ± 30 and 535 ± 30 nm using filters with the appropriate band pass. Ligands or vehicle were then added after two to four base-line readings. Data are presented as a BRET ratio, calculated as the ratio of YFP to Rlu8 signals and corrected for vehicle. Alternatively, for end point experiments, coelenterazine h was added 10 min before BRET detection, and ligands were added at various time points as described under “Results.” End point assay data are reported in milli-BRET units corrected for vehicle.

**Immunocytochemistry and Confocal Microscopy—** HEK293 cells growing on poly-D-lysine-coated glass coverslips were transfected with 1 μg of c-myc-M₁. After 48 h, cells were incubated with or without ligands (10 μM) for 4 h in the presence of 10 μg/ml cycloheximide. Cells were washed in phosphate-buffered saline (PBS), pH 7.4, fixed in 4% paraformaldehyde in PBS, and then incubated in blocking buffer (3% v/v normal goat serum, 0.1% Triton X-100 in PBS). Primary antibody (9E10, 2 μg/ml) was applied in blocking buffer at 4 °C overnight. Secondary antibody (Alexa-Fluor 594-conjugated goat anti-mouse IgG) was applied for 1 h at room temperature. Coverslips were mounted with ProLong Gold. Images were captured using a Leica TCS SP8 laser scanning confocal microscope (North Ryde, NSW, Australia).

**Data Analysis—** Data analysis was performed using GraphPad Prism v. 6.0. All affinity and potency values were estimated as logarithms (18). Concentration-response curves for the interaction between allosteric and orthosteric ligands were globally fitted to the following operational model of allosterism and agonism (19),

\[
E = \frac{E_m(\tau_A[A](K_a + \alpha\beta[B]) + \tau_B[B][K_a])^n}{([A]K_a + K_D[\alpha][\beta][B] + [A]\alpha[B][B]^n + (\tau_A[A](K_a + \alpha\beta[B]) + \tau_B[B][K_a])^n} \quad \text{(Eq. 1)}
\]

where \(E_m\) is the maximum possible cellular response, \([A]\) and \([B]\) are the concentrations of orthosteric and allosteric ligands, respectively, \(K_a\) and \(K_D\) are the equilibrium dissociation constant of the orthosteric and allosteric ligands, respectively, \(\tau_A\) and \(\tau_B\) are operational measures of orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and receptor density), respectively, \(\alpha\) is the binding cooperativity parameter between the orthosteric and allosteric ligand, and \(\beta\) denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric agonist.

Data are reported as the mean ± S.E., and statistical comparisons between values were by Student’s t test or analysis of variance with Tukey’s multiple comparison post-test as appropriate. A value of \(p < 0.05\) was considered statistically significant.

**RESULTS**

**β-Arrestin-2 Recruitment to the M₁ mAChR Is GRK2 and Gα₁-dependent—** We investigated the recruitment of β-arrestins to the M₁ mAChR using BRET. To quantitatively assess the interactions between M₁ mAChRs and β-arrestin-1 or β-arrestin-2, cells were co-transfected with Rlu8-tagged M₁ mAChR and YFP-tagged β-arrestins. Kinetic BRET measurements revealed that stimulation with 1 mM CCh led to a rapid increase in the association of the M₁ mAChR with β-arrestin-2 (Fig. 1A). Subsequent addition of the orthosteric antagonist, atropine (10 μM), immediately inhibited the energy transfer between the M₁ mAChR and β-arrestin-2 (Fig. 1A). As the BRET signal had reached its maximum after 5 min of incubation with CCh, we constructed concentration-response curves at this time point. M₁ mAChR activation induced a concentration-dependent recruitment of β-arrestin-1 and β-arrestin-2 (Fig. 1B). Interestingly, the \(E_{\max}\) of β-arrestin-1 recruitment was significantly lower than that of β-arrestin-2. Although this difference could be due to a true preference for β-arrestin-2 over β-arrestin-1, this effect can also be explained by different conformations or dipole orientations of the two β-arrestin-YFP proteins, resulting in different energy transfer efficiencies.

Phosphorylation of serine and threonine residues in GPCRs by GRKs, such as GRK2, increases the affinity of the receptor for β-arrestins. Previous studies using purified proteins or over-expression of dominant negative constructs have suggested a role for GRK2 in M₁ mAChR phosphorylation (20–22). CCh-induced recruitment of YFP-β-arrestin-2 to M₁ Rlu8 was attenuated when cells were preincubated with the GRK2 inhibitor 103A (23), resulting in reductions in both potency and \(E_{\max}\) (Fig. 1C). Thus, β-arrestin-2 recruitment to the M₁ mAChR is partially dependent on phosphorylation of the receptor by GRK2.

It is also well accepted that β-arrestin recruitment to GPCRs can occur in the absence of G protein coupling (24). However,
inhibition of Go with the specific inhibitor UBO-QIC reduced the maximum recruitment of β-arrestin-2 by 35% (Fig. 1D), suggesting that for the M1 mAChR, β-arrestin recruitment is also G protein-dependent.

We have previously described an ICL3 deletion M1 mAChR (M1ΔI3 mAChR) that retains full signaling capability via Goq (8). This construct lacks all potential phosphorylation sites within ICL3, except two serines and threonines in the N- and C-terminal portions of the loop. We first determined the potency of CCh to induce β-arrestin-2 recruitment to the M1ΔI3mAChR (Fig. 2A). After a 5-min incubation, the pEC50 of CCh at this mutant receptor was not significantly different to WT. However, despite comparable CCh affinity and cell surface expression (data not shown), maximum recruitment to the M1ΔI3mAChR was only one-fifth of the WT Fmax.

Interestingly, the rate of β-arrestin-2 recruitment to this truncated receptor was also different from that observed at the WT receptor, with a slow onset and no obvious plateau reached even after 20 min (Fig. 2B). To gain a better understanding of the dynamics of the β-arrestin-2 interaction with WT and ΔI3receptors, we measured the BRET signal after prolonged incubation with 1 μM CCh in the presence of cycloheximide (Fig. 2C). The CCh-induced BRET signal between WT M1-Rluc8 and YFP-β-arrestin-2 started to decline after 20 min and had reached base-line levels by 60 min. In contrast, the association of M1ΔI3-Rluc8 with YFP-β-arrestin-2 was maintained for at least 2 h despite the limited initial recruitment of YFP-β-arrestin-2. These results thus suggest that the ICL3 of the M1 mAChR contains the key components that determine the dynamics of the interaction with β-arrestin-2.

In family A GPCRs, the conserved (E/D)RY motif at the intracellular end of transmembrane domain III is critical for G protein activation (25). Mutation of the arginine residue within this motif at the M1 mAChR compromised G protein activation but not β-arrestin recruitment (26). We, therefore, investigated the effect of the equivalent mutation at the M1 mAChR. The R123L mutant M1 mAChR exhibited severely compromised signaling via Goq as revealed by a large rightward shift in the CCh concentration-response curve for calcium mobilization (Fig. 3A), confirming the role of this residue in G protein coupling to M1 mAChRs. However, in contrast to the observations at the M1 mAChR, β-arrestin-2 recruitment to the M1R123L mAChR was also significantly reduced when compared with wild type. The effect of such a mutation was observed as both a reduction in CCh efficacy (Fig. 3B) as well as shortened duration of the association of the receptor with YFP-β-arrestin-2 (Fig. 3C). Such impaired arrestin recruitment was not due to reduced receptor expression, as [3H]NMS saturation binding was comparable with wild type (data not shown). These results together with the UBO-QIC inhibitor effect confirm that β-arrestin recruitment at the M1 mAChR depends on G protein activation.

**CCh-induced M1 mAChR Internalization—β-Arrestins have classically been implicated in GPCR signal termination and internalization.** We used an anti-myc ELISA on whole cells to identify cell surface c-myc-M1 mAChRs remaining after incubation with ligand at 37 °C (in the presence of the de novo protein synthesis inhibitor cycloheximide). CCh induced a concentration and time-dependent loss of surface receptors to a maximum of ~30% after 4 h (Fig. 4A). Hypertonic sucrose and the clathrin terminal domain inhibitor, Pitstop 2 (27), prevented CCh-induced internalization of the c-myc-M1 mAChR (Fig. 4B). However, when cells were pretreated with the dynamin I/II inhibitor dynasore (28), we could not detect a significant effect of this inhibitor on M1 mAChR internalization (Fig. 4B).
As both the \( M_1 \) R123L and \( M_1 \Delta i3 \) receptors exhibited severely compromised \( \beta \)-arrestin-2 recruitment, we used them as tools to investigate the role of this scaffolding protein in \( M_1 \) mAChR internalization. After a 4-h incubation with increasing concentrations of CCh, both mutant receptors exhibited reduced maximum internalization compared with WT as detected with [3H]NMS binding (Fig. 4). The potency of CCh at both mutants was also significantly reduced compared with WT. Because the internalization results mirror the ability of each receptor to recruit \( \beta \)-arrestin-2, they suggest that \( \beta \)-arrestin recruitment plays a key role in the internalization of the \( M_1 \) mAChR.

**BQCA Is a Positive Allosteric Modulator of \( M_1 \) mAChR Signaling and \( \beta \)-Arrestin-2 Recruitment**—The ability of BQCA to potentiate the acute responses to CCh was investigated in cells stably expressing the \( M_1 \) mAChR. Inositol 1-phosphate accumulation was used as a canonical measure of \( M_1 \) mAChR activation resulting from preferential activation of \( G_{q} \) proteins. As expected, BQCA robustly potentiated CCh-mediated inositol 1-phosphate accumulation in a concentration-dependent manner.
manner. In addition, and as previously described, BQCA displayed moderate agonism on its own (Fig. 5A, Table 1).

We then tested the effect of BQCA on the recruitment of β-arrestin-2 to the M₁ mACHR. BQCA on its own did not induce significant β-arrestin-2 recruitment to the wild type receptor (Fig. 5B). However, in agreement with its modulatory activity, BQCA potentiated the effect of CCh on β-arrestin-2 recruitment (estimated allosteric parameters shown in Table 1). These results demonstrate that BQCA positively modulates the recruitment of β-arrestin-2 to the M₁ mACHR.

We also investigated whether BQCA was able to potentiate β-arrestin-2 recruitment at the mutant M₁ mACHRs that lacks ICL3 or show compromised G protein coupling. As shown in Table 2, co-incubation of CCh with 10 μM BQCA induced the same degree of modulation at both mutants, which was similar to the potentiation observed at the wild type receptor, without changes in the Eₘₐₓ.

Effects of BQCA on Endocytic Trafficking of the M₁ mACHR—To further investigate the fate of M₁ mACHRs upon incubation with CCh with or without BQCA, we used immunocytochemistry and sequential confocal imaging. In unstimulated HEK293 cells, c-myc-M₁ mACHRs were largely at the plasma membrane in untreated cells. c-myc-M₁ mACHR immunostaining in CCh-treated cells was localized in punctate, vesicular structures. Similarly, in cells treated with CCh + BQCA, c-myc-M₁ mACHR immunostaining was punctate, with little plasma membrane localization. The scale bar (10 μm) applies to all photomicrographs. B, CCh-mediated M₁ mACHR internalization was increased after co-incubation with 10 μM BQCA. Surface receptors were detected by anti-myc ELISA. n = 4. The asterisk indicates significantly different Eₘₐₓ (*, p < 0.05).

![FIGURE 5. BQCA is a positive allosteric modulator of M₁, mACHR signaling and β-arrestin recruitment.](image)

**TABLE 1**

Allosteric parameters for the functional interaction between CCh and BQCA at the M₁ mACHR

| Parameter | IP₁ | β-Arrestin-2 |
|-----------|-----|--------------|
| pKᵦ       | 3.98| 3.98         |
| Log aβ     | 3.16 ± 0.16 (a, 1445) | 2.14 ± 0.18 (a, 138) |
| Log τₑ     | 0.63 ± 0.17 | 0.24 ± 0.25 |

* Negative logarithm of the equilibrium dissociation constant of BQCA; value was fixed to that determined from radioligand binding assays at the wild type M₁ mACHR (8).

| Parameter | IP₁ | β-Arrestin-2 |
|-----------|-----|--------------|
| Log aβ     | 3.16 ± 0.16 (a, 1445) | 2.14 ± 0.18 (a, 138) |
| Log τₑ     | 0.63 ± 0.17 | 0.24 ± 0.25 |

* Logarithm of the product of the binding cooperativity (α) and activation modulation (β) factors between CCh and BQCA. The anti-logarithm is shown in parentheses.

* Logarithm of the operational efficacy parameter of BQCA as an allosteric agonist.

**TABLE 2**

Effect of BQCA on CCh-induced β-arrestin recruitment at WT, Δi3, and R123L M₁ mACHRs

| Receptor | pEC₅₀ | Eₘₐₓ | pEC₅₀ | Eₘₐₓ |
|----------|-------|------|-------|------|
| WT       | 4.54 ± 0.06 | 57.01 ± 4.72 | 6.23 ± 0.28 | 66.05 ± 7.23 |
| Δi3      | 4.59 ± 0.18 | 22.73 ± 6.13 | 6.21 ± 0.26 | 27.07 ± 5.65 |
| R123L    | 4.15 ± 0.32 | 14.52 ± 3.72 | 5.36 ± 0.24 | 18.90 ± 5.44 |

* Significant effect of BQCA: p < 0.0001.

* Significant difference from WT: p < 0.01.

* Significant difference from WT: p < 0.001.

* Significant effect of BQCA: p < 0.05.

* Significant difference from WT: p < 0.0001.

* Significant effect of BQCA: p < 0.05.

![FIGURE 6. Effect of BQCA on M₁, mACHR internalization.](image)
described BRET assay that allows the detection of energy transfer between receptors and BRET partners targeted to defined subcellular compartments in live cells (15, 29, 30). M1-RLuc8 was co-expressed in HEK293 cells with one of three Venus-tagged BRET acceptors localized to different subcellular compartments: Venus-Rab5a in early endosomes, Venus-Rab7a in late endosomes/lysosomes, and Venus-Rab11 in recycling endosomes (Fig. 7A). Cells were incubated with CCh or CCh plus BQCA (both at 10 μΜ) at 37 °C in the presence of cycloheximide to prevent de novo protein synthesis. BRET was measured after 0–4 h in the presence of ligands. Alternatively, BRET was measured after a combination of 4-h ligand incubation, thorough washing, and 2 h in the absence of ligand to investigate receptor recycling. This washing protocol resulted in complete removal of ligand (data not shown). The RLuc substrate coelenterazine h was added in the last 10 min of agonist incubation before BRET measurements.

Incubation of M1-RLuc8-expressing cells with CCh led to a significant increase in BRET signal with Venus-Rab5a or Venus-Rab11 within 10 min (Fig. 7B, top and bottom panels). Both Rab5a and Rab11 BRET showed a trend to return to baseline 2 h after CCh washout. In contrast, Rab7a BRET remained close to baseline levels throughout the CCh incubation period (Fig. 7B, middle panel). These findings suggest internalized M1 mACHRs rapidly enter the early and recycling endosome pools upon activation, whereas transit into lysosomes occurs only after prolonged ligand incubation.

The addition of BQCA alone (10 μΜ) to M1-RLuc8-transfected cells increased BRET in the Rab5a- and Rab11-transfected cells but only at 30 and 60 min, respectively (Fig. 7B). Interestingly, co-addition of CCh and BQCA resulted in a significant increase in the BRET signal in all three compartments. It is important to note that the effect of BQCA on CCh-induced BRET can only be assessed at one donor-acceptor pair (31). Differences between two different BRET pairs cannot be evaluated due to the potential effects of protein conformations and dipole orientations discussed above. As such, the smaller increase in ligand-induced BRET between M1-RLuc8 and Venus-Rab7a, compared with the other Rab markers, does not necessarily mean a smaller effect on trafficking to this compartment.

To rule out simple additive agonism as the cause of the increased ligand-induced BRET signal, we constructed concentration-response curves for CCh in the absence or presence of 10 μΜ BQCA. We measured ligand-induced BRET after 4 h for Rab5a and Rab7a or after ligand washout for Rab11 (Fig. 7C). In contrast to the ELISA for surface receptors, we could detect significant modulation by BQCA. BQCA increased the potency of CCh-mediated M1-RLuc8 BRET with Rab5a (2.4-fold), Rab7a (5-fold), and Rab11 (13-fold) with negligible agonism. These data confirm that BQCA acts as a positive allosteric modulator at the level of M1 mACHR trafficking.

Taken together these results support the hypothesis that BQCA potentiates CCh-induced M1 mACHR internalization. Our BRET results show that BQCA has a significant impact on
endosomal trafficking dynamics of the M₁ mAChR and also highlight the utility of this sensitive resonance energy transfer approach to delineate such receptor regulatory events.

**BQCA Modulates M₁ mAChR Recycling and Degradation**—
Once internalized, GPCRs can be recycled back to the plasma membrane or sorted to lysosomal compartments and subsequent degradation. As we detected the presence of M₁ mAChR in Rab11⁺ (recycling) endosomes upon removal of ligand (Fig. 7B), we investigated whether M₁ mAChRs returned to the plasma membrane after agonist removal.

Surface receptors were detected using the anti-myc ELISA. CCh with or without 10 μM BQCA was applied to cells for 4 h followed by agonist washout and a further 2-h incubation in the absence of ligand. As shown previously, incubation with all ligands for 4 h led to a significant reduction in surface receptor levels compared with vehicle (Fig. 8A). Removal of the ligand resulted in an overall increase of surface receptor levels, except for treatment with BQCA alone, which remained at the prewashout level. These results support the previous BRET results and confirm that the M₁ mAChR recycles to the cell surface upon agonist removal. However, we were unable to inhibit M₁ mAChR recycling using either the vacuolar H⁺-ATPase inhibitor bafilomycin A1 or the protein secretion inhibitor brefeldin A (Fig. 8B), indicating that neither endosome acidification nor Golgi function was required for the return of M₁ mAChR to the plasma membrane.

The presence of M₁ mAChRs in the Rab7a subcellular compartment (Fig. 7B) suggested that some M₁ mAChRs might be targeted to the late endosomes/lysosomes. We, therefore, investigated the extent of receptor degradation after different ligand combinations using a whole cell anti-myc ELISA on permeabilized cells (Fig. 8C). The total amount of receptors was not affected after incubation with CCh or BQCA alone followed by ligand washout, a significant decrease was observed after washout of CCh and BQCA as well as when BQCA was maintained in the recovery media (Fig. 8C). These results are in agreement with our previous results and suggest that the proportion of M₁ mAChRs that traffic to lysosomes is increased upon incubation of CCh with BQCA.

**DISCUSSION**
Because of their improved receptor subtype selectivity, allosteric ligands represent an attractive approach for the development of novel therapies. However, as the net effect of any receptor-based therapy reflects the interplay between acute signaling and longer term regulatory pathways, it is crucial to understand not only the acute but also the chronic effects of allosteric drugs at their corresponding GPCR target (11). M₁ mAChR allosteric modulators have been proposed as potential therapeutics for various CNS disorders (33). However, our understanding of their effects on receptor regulatory processes such as receptor internalization and subcellular trafficking is still limited. In the current study we have evaluated these effects for the M₁ mAChR allosteric modulator BQCA, which is an unprecedented example of an allosteric modulator with very high selectivity and positive cooperativity with ACh at the M₁ mAChR (6, 8). Pharmacologically, BQCA displays simple receptor "state dependence" and does not engender stimulus bias (8, 17), in contrast to previously reported mAChR allosteric modulators such as LY2033298 (10). As such, BQCA is an ideal chemical tool with which to assess how allosteric ligands can affect receptor levels and trafficking dynamics in a model system. Our results show that in heterologously expressing cells, M₁ mAChRs recruit β-arrestins and internalize upon agonist stimulation. BQCA positively modulates β-arrestin recruitment to the M₁ mAChR and potentiates subcellular trafficking of the receptor via the different endocytic compartments.

The role of β-arrestins in mAChR regulation has been explored previously, and it was suggested that although both isoforms (β-arrestin-1 and -2) were implicated in M₁ mAChR regulation (34), they were not required for receptor internalization (35). We show that the M₁ mAChR recruits β-arrestins 1 and 2 within minutes of its activation by CCh. Recruitment of β-arrestin-2 occurs via a mechanism that involves, at least partially, the kinase activity of GRK2. Additionally, using β-arres-
GPCR Trafficking by Allosteric Ligands

tin recruitment-compromised M₁ mAChR mutants (Δi3 and R123L), our results suggest that binding of this scaffolding protein to the activated receptor is necessary for internalization. Importantly, our results also emphasize two mechanistic features of M₁ mAChR regulation. First, the dynamics of the interaction between β-arrestin-2 and the M₁ mAChR may be dictated by other proteins that also bind to ICL3, suggesting a potential mechanism for the previous observations of compromised internalization of truncated M₁ mAChRs (36). Second, recruitment of β-arrestin to the M₁ mAChR requires G protein activation, as abrogating G protein coupling to the receptor has a significant impact not only on arrestin recruitment but also on receptor internalization, which is different from observations at the M₄ mAChR (26).

BQCA has been described as a positive allosteric modulator based on its effects on the actions of ACh in canonical signaling pathways linked to M₁ mAChR activation. Our study shows that this behavior extends to potentiation of β-arrestin recruitment and endocytic trafficking. Interestingly, we did not detect substantial allosteric agonism by BQCA in the β-arrestin recruitment BRET assay. This latter result aligns with the previous descriptions of BQCA behavior in that β-arrestin recruitment is a very proximal event to receptor activation subject to minimal amplification. Because the degree of direct agonism in the actions of BQCA is primarily a function of cellular stimulus-response coupling efficiency, it is anticipated that little or no agonism of BQCA would be detected when measuring β-arrestin recruitment (8). This expectation is also applicable to other regulatory processes such as internalization and endocytic trafficking. Moreover, the effect of BQCA on M₁ mAChR mutants with compromised internalization also aligns with previous observations that establish BQCA as an allosteric modulator whose effects are mainly mediated by positive cooperativity of receptor affinity and limited cooperativity in terms of receptor efficacy. In contrast, this is not the case for the M₄ mAChR-selective allosteric ligand, LY2033298, which engenders stimulus bias at the M₄ mAChR, whereby the degree of potentiation does not track with the stimulus-response coupling efficiency and, therefore, allows for more complex agonistic behaviors (10).

Once internalized, receptors can be directed to degradative pathways (receptor down-regulation) or recycled back to the cell surface (37). Receptor trafficking through the endocytic machinery as well as the fate of internalized receptors is agonist-dependent (38–40). Using a novel quantitative BRET approach (15, 29) we show for the first time the subcellular trafficking of the M₁ mAChR upon CCh stimulation. This approach provides a complementary method to immunocytochemistry and allows for the quantification of ligand-dependent effects on receptor trafficking (15, 29). Within 10 min of CCh incubation, M₁ mAChRs trafficked into Rab5⁺ early endosomes and Rab11⁺ recycling endosomes. Co-incubation of CCh with BQCA had a marked effect on the trafficking of the M₁ mAChR. Although it did not change the trafficking profile, BQCA increased the BRET signal from receptors localized within the different subcellular compartments, especially Rab5a- and Rab11-containing endosomes. Moreover, this effect is due to an increase in CCh potency at all three BRET pairs, ruling out a simple additive effect. Therefore, although we could not detect BQCA-induced modulation of internalization of the WT M₁ mAChR using whole cell ELISA, more sensitive approaches such as BRET allow us for the first time to assess allosteric modulation of receptor trafficking.

Further validation of the BRET approach is supported by the fact that ELISA experiments performed after agonist washout show the recovery of receptor at the cell surface, which is in agreement with the localization of M₁ mAChRs in Rab11⁺ endosomes. However, this recycling could not be blocked by inhibitors of endosomal acidification, such as bafilomycin A1, or by Golgi disruption. Hence, alternate mechanisms of receptor recycling may be responsible for M₁ mAChR recovery. Finally, when cells were treated with both CCh and BQCA, BRET between M₁-Rluc8 and Venus-Rab7a decreased after ligand washout, indicative of movement out of this compartment into the lysosome. This suggested that prolonged incubation followed by washout of CCh plus BQCA might lead to increased receptor degradation. This was confirmed using ELISA to detect total receptor expression, which only decreased when cells were incubated with CCh and BQCA and not when either ligand was added individually. These results are in line with our trafficking data and suggest that potentiation of the M₁ mAChR by BQCA increases the relative amount of receptor targeted for degradation.

Allosteric modulators have emerged as promising alternatives for the subtype-selective targeting of GPCRs. Therefore, it will be important to determine how this class of ligands regulates their target GPCR. In addition to BQCA, modulation of mAChR internalization has been demonstrated previously by the mAChR negative allosteric ligand gallamine at the M₂ mAChR and by LY2033298 at the M₄ mAChR. Gallamine decreases CCh-induced M₂ mAChR internalization and up-regulates cell surface receptor levels (41). In contrast, LY2033298 potentiates ACh-induced M₄ mAChR internalization to a greater extent than would be predicted from acute signaling assays, effectively demonstrating a biased action toward regulatory pathways (10). Our results show that in heterologous systems a positive allosteric modulator of the M₁ mAChR also behaves as such with regard to receptor regulation without evidence of bias. However, this remains to be validated in more physiologically relevant systems. Unfortunately, to our knowledge there are no neuronal cell lines validated for the study of endogenous M₁ mAChRs. In addition, the lack of reliable M₁ mAChR specific antibodies is a significant obstacle to the evaluation of the trafficking of these receptors in primary neuronal cultures. Development of more subtype selective probes to investigate mAChR trafficking will be of great significance to translate our findings into native expression systems.

In summary, the allosteric ligand BQCA modulates M₁ mAChR regulation; it enhances β-arrestin recruitment and receptor trafficking to intracellular endocytic compartments. This has significant therapeutic implications when considering prolonged exposure to this new class of ligands.

Acknowledgments—We thank Marc Caron (Duke University) for the YFP-β-arrestin-1 and -2 constructs and Jurgen Wess (NIDDK, National Institutes of Health) for the p416GPD-M₁ Δi3 construct.
ang, Y.-J., Höllt, V., and Koch, T. (2008) Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J. Neurochem. 104, 1132–1143

39. Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y., and von Zastrow, M. (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23, 737–746

40. Raote, I., Bhattacharyya, S., and Panicker, M. M. (2013) Functional selectivity in serotonin receptor 2A (5-HT2A) endocytosis, recycling, and phosphorylation. Mol. Pharmacol. 83, 42–50

41. May, L. T., Lin, Y., Sexton, P. M., and Christopoulos, A. (2005) Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J. Pharmacol. Exp. Ther. 312, 382–390